▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2720 by analyst upside · 2026-11-12
RGEN
Repligen Corporation
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+17.7%
implied upside to consensus target
Current Price $172.62
Consensus Target $203.21
Bull Target $235.0
Bear Target $175.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
12
Hold
4
Sell
0
52-Week Low $100.99
52-Week High $198.87
YTD Return +5.0%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E 65.1x
EPS (TTM) $-0.21
PEG Ratio 1.68
Dividend Yield N/A
Revenue (TTM) $806M
Profit Margin -1.5%
52-WEEK RANGE
52-Week Low $100.99
52-Week High $198.87
Current Price $172.62
Bear Target $175.0
Bull Target $235.0
● Now $172.62 ● Target $203.21
TRADING DATA
Avg Volume 1.2M
YTD Return +5.0%
Analyst Count 19
Consensus Buy
Upside to Target +17.7%
Last Updated 2026-11-12

ANALYST SUMMARY

Repligen Corporation (RGEN) is currently trading at $172.62 with a Wall Street consensus price target of $203.21, implying potential upside of 17.7% over the next 12 months. 19 analysts currently cover RGEN, with a consensus rating of Buy - 79% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $235.0, while the most cautious has a target of $175.0.

RGEN operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 5.0% year-to-date and is currently trading near the upper end of its 52-week range of $100.99 – $198.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

UHS -0.8%
Universal Health Services, Inc.
$11B · P/E 8.2x · Hold
GMED +23.9%
Globus Medical, Inc.
$10B · P/E 18.5x · Buy
HSIC +9.3%
Henry Schein, Inc.
$10B · P/E 24.3x · Buy
ENSG +21.3%
The Ensign Group, Inc.
$11B · P/E 27.5x · Buy
FMS +0.1%
Fresenius Medical Care AG
$12B · P/E 13.1x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for RGEN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-10-28 Building track record
Canaccord Genuity - Reiterated
Hold → Hold 2026-10-19 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-10-07 Building track record
UBS - Reiterated
Buy → Buy 2026-09-09 33% win rate (6 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-30 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-07-29 43% win rate (7 calls)
Benchmark ↑ Upgrade
Hold → Buy 2026-07-07 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-07-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
23/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →